Repurposing Reports

Disease-specific dossiers ranking known, approved drugs as repurposing candidates — scored for reversal of the disease expression profile, cytotoxicity-filtered, prioritized by ChEMBL clinical maturity, cross-checked against ClinicalTrials.gov whitespace.

Computational, pending wet-lab. Ranked, mechanism-grounded hypotheses to triage and de-risk programs — not clinical evidence, efficacy claims, or treatment advice. Known approved compounds only (no novel composition disclosed). 95 reports across 9 areas · generated 2026-06-22.

Renal & Hepatic 12

S2 (505(b)(2))

Acute Liver Failure

Top approved-drug candidatesmenadione, perhexiline, chloroquine, azacitidine

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Diabetic Kidney Disease

Top approved-drug candidatesnilotinib, lovastatin, rosiglitazone, neratinib

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Diabetic Nephropathy

Top approved-drug candidatesprocyclidine, lenalidomide, cyclopentolate, thalidomide

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Focal Segmental Glomerulosclerosis

Top approved-drug candidatesteniposide, atracurium, topotecan, amsacrine

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Glomerulosclerosis

Top approved-drug candidatesverteporfin, mibefradil, fluspirilene, flunisolide

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Henoch-Schonlein Purpura Nephritis

Top approved-drug candidatesauranofin, sotalol, dexamethasone, wortmannin

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

IgA Nephropathy

Top approved-drug candidatesmycophenolate-mofetil, sildenafil, rucaparib, oxymetazoline

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Kidney disorder associated with type 2 diabetes mellitus

Top approved-drug candidatessorafenib, artesunate, vemurafenib, nilotinib

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Membranous Nephropathy

Top approved-drug candidatesverteporfin, mibefradil, ziprasidone, flunisolide

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Non-Alcoholic Fatty Liver Disease

Top approved-drug candidatesniclosamide, verteporfin, pirenzepine, levocabastine

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

liver cirrhosis

Top approved-drug candidatesdextromethorphan, azacitidine, tegaserod, tacrolimus

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

renal cell carcinoma

Top approved-drug candidatesidarubicin, dactinomycin, simvastatin, ribavirin

Prior clinical activity

$3,950Details Acquire

Cardiovascular 10

S2 (505(b)(2))

Acute Myocardial Infarction

Top approved-drug candidatesiloprost, flunarizine, floxuridine, isotretinoin

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Atherosclerosis

Top approved-drug candidatesephedrine, cilostazol, papaverine, simvastatin

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Cardiomyopathy

Top approved-drug candidatesranitidine, proscillaridin, ivermectin, idarubicin

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Coronary Artery Disease

Top approved-drug candidatesdasatinib, guaifenesin, lovastatin, nitrendipine

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Dilated Cardiomyopathy

Top approved-drug candidatesauranofin, prednicarbate, nilotinib, dopamine

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Heart Failure

Top approved-drug candidatesixazomib, ziprasidone, fluspirilene, prilocaine

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Intracranial Aneurysm

Top approved-drug candidatesdiazoxide, vorinostat, verapamil, sirolimus

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Pulmonary Arterial Hypertension

Top approved-drug candidatesclarithromycin, atracurium, teniposide, idarubicin

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

congestive heart failure

Top approved-drug candidatesteniposide, cisapride, pyrazinamide, topiramate

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

pulmonary hypertension

Top approved-drug candidatesnaltrexone, sulfasalazine, aliskiren, noscapine

Prior clinical activity

$3,950Details Acquire

Immune & Inflammation 8

S2 (505(b)(2))

Allergic Disorder of Respiratory System

Top approved-drug candidatesgemcitabine, quinapril, lovastatin, cilostazol

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Asthma

Top approved-drug candidatestienilic-acid, ethambutol, probenecid, pirfenidone

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Atopic Dermatitis

Top approved-drug candidatesatracurium, clarithromycin, teniposide, phensuximide

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Crohn's Disease

Top approved-drug candidatesSB-590885, sirolimus, barasertib-HQPA, SU-11274

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Psoriasis

Top approved-drug candidatesvemurafenib, selumetinib, neratinib, midostaurin

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Rheumatoid Arthritis

Top approved-drug candidatessirolimus, betamethasone, crizotinib, decitabine

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Systemic Lupus Erythematosus

Top approved-drug candidatesperhexiline, ixazomib, niclosamide, menadione

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Ulcerative Colitis

Top approved-drug candidateslamivudine, neratinib, cyclopenthiazide, atorvastatin

CT.gov whitespace: untried

$3,950Details Acquire

Cognitive & Neuro 11

S2 (505(b)(2))

Alzheimer's Disease

Top approved-drug candidatestetrabenazine, amiodarone, chlorpromazine, doxercalciferol

CT.gov whitespace: untried

$3,950Details Acquire

S3 (505(b)(2)+Orphan) · Orphan-eligible

Amyotrophic Lateral Sclerosis

Top approved-drug candidatestropisetron, ixazomib, donepezil, quizartinib

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Autism Spectrum Disorder

Top approved-drug candidatesidarubicin, sirolimus, mebendazole, gemcitabine

Prior clinical activity

$3,950Details Acquire

S3 (505(b)(2)+Orphan) · Orphan-eligible

Friedreich Ataxia

Top approved-drug candidatesvemurafenib, selumetinib, tivozanib, bosutinib

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Frontotemporal Dementia

Top approved-drug candidatesidarubicin, epirubicin, dactinomycin, olaparib

CT.gov whitespace: untried

$3,950Details Acquire

S3 (505(b)(2)+Orphan) · Orphan-eligible

Huntington's Disease

Top approved-drug candidatespalbociclib, atracurium, idarubicin, teniposide

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Multiple Sclerosis

Top approved-drug candidatestretinoin, retinol, crizotinib, bisacodyl

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Parkinson's Disease

Top approved-drug candidatesatorvastatin, rosuvastatin, tretinoin, selumetinib

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Schizophrenia

Top approved-drug candidatesthalidomide, danazol, cytarabine, xanthinol

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

epilepsy syndrome

Top approved-drug candidatessulindac, pentoxifylline, cisapride, oxaprozin

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

mental depression

Top approved-drug candidatessimvastatin, ciprofibrate, olaparib, prazosin

Prior clinical activity

$3,950Details Acquire

Anti-Infective 10

S2 (505(b)(2))

COVID-19

Top approved-drug candidatesnifedipine, etomoxir, lestaurtinib, AR-C133057XX

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

HIV encephalitis

Top approved-drug candidatesmidazolam, ipratropium, carteolol, vorinostat

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Hepatitis C

Top approved-drug candidatesdactinomycin, epirubicin, auranofin, idarubicin

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Idiopathic Pulmonary Fibrosis;Non-Specific Interstitial Pneumonia

Top approved-drug candidatesclarithromycin, atracurium, idarubicin, amiodarone

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Influenza

Top approved-drug candidatesnifedipine, rosiglitazone, rucaparib, dasatinib

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Non-Specific Interstitial Pneumonia

Top approved-drug candidatesnilotinib, panobinostat, danazol, niclosamide

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Pulmonary Tuberculosis

Top approved-drug candidatesmitotane, amiodarone, vorinostat, sirolimus

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Sepsis

Top approved-drug candidatesnifedipine, rucaparib, vidarabine, fulvestrant

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Tuberculosis

Top approved-drug candidatesdasatinib, vemurafenib, vorinostat, panobinostat

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

swine influenza

Top approved-drug candidatesbudesonide, cefuroxime, mifepristone, nilotinib

CT.gov whitespace: untried

$3,950Details Acquire

Oncology 15

S2 (505(b)(2))

Colon Cancer

Top approved-drug candidatesproscillaridin, midazolam, digoxin, fenbufen

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Colorectal Carcinoma

Top approved-drug candidatesbelinostat, idarubicin, ketorolac, panobinostat

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Gastric Cancer

Top approved-drug candidatestretinoin, clonidine, mitotane, vemurafenib

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Lung Adenocarcinoma

Top approved-drug candidatesvorinostat, selumetinib, neratinib, belinostat

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Lung Cancer

Top approved-drug candidatesvorinostat, trichostatin-a, AZ-628, panobinostat

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Multiple Myeloma

Top approved-drug candidatesnifedipine, troglitazone, fulvestrant, atovaquone

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Prostate Cancer

Top approved-drug candidatesmidostaurin, etoposide, mitoxantrone, proscillaridin

Prior clinical activity

$3,950Details Acquire

Repurposing report

Top approved-drug candidatesranked candidates

Whitespace: under review

$3,950Details Acquire

S2 (505(b)(2))

Retinoblastoma

Top approved-drug candidatesdasatinib, estradiol, toremifene, selumetinib

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

acute T cell leukemia

Top approved-drug candidatesnefopam, phenolphthalein, vorinostat, artesunate

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

breast cancer

Top approved-drug candidatesmephentermine, doxazosin, idarubicin, tolmetin

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

colorectal cancer

Top approved-drug candidatesnorethindrone, levonorgestrel, exemestane, oxymetholone

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

glioblastoma multiforme

Top approved-drug candidatesgatifloxacin, sulpiride, indometacin, indoprofen

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

melanoma

Top approved-drug candidatespazopanib, loxapine, chlorpromazine, amiodarone

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

pancreatic cancer

Top approved-drug candidatesdantron, pindolol, nadolol, valproic-acid

CT.gov whitespace: untried

$3,950Details Acquire

Musculoskeletal 11

S3 (505(b)(2)+Orphan) · Orphan-eligible

Dermatomyositis

Top approved-drug candidatesfamotidine, dexamethasone, butoconazole, nitrendipine

CT.gov whitespace: untried

$3,950Details Acquire

S3 (505(b)(2)+Orphan) · Orphan-eligible

Duchenne muscular dystrophy

Top approved-drug candidatesrimexolone, labetalol, dihydroergotamine, glibenclamide

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Inclusion Body Myositis

Top approved-drug candidateslosartan, vorinostat, carbamazepine, fulvestrant

CT.gov whitespace: untried

$3,950Details Acquire

S3 (505(b)(2)+Orphan) · Orphan-eligible

Juvenile Dermatomyositis

Top approved-drug candidatesparoxetine, lovastatin, niclosamide, bisacodyl

CT.gov whitespace: untried

$3,950Details Acquire

S3 (505(b)(2)+Orphan) · Orphan-eligible

Limb-Girdle Muscular Dystrophy Type 2A

Top approved-drug candidatesdexamethasone, temozolomide, quizartinib, vemurafenib

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Mitochondrial Myopathy; Encephalopathy; Lactic Acidosis; And Stroke-Like Episodes

Top approved-drug candidatessirolimus, rilmenidine, temozolomide, dexamethasone

CT.gov whitespace: untried

$3,950Details Acquire

S3 (505(b)(2)+Orphan) · Orphan-eligible

Muscular Dystrophy

Top approved-drug candidatesdasatinib, valproic-acid, irinotecan, axitinib

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Myositis

Top approved-drug candidatesdasatinib, dexamethasone, raltitrexed, rizatriptan

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Osteoarthritis

Top approved-drug candidatessibutramine, ipratropium, pentobarbital, dolasetron

CT.gov whitespace: untried

$3,950Details Acquire

S3 (505(b)(2)+Orphan) · Orphan-eligible

Sarcopenia

Top approved-drug candidatesipratropium, disopyramide, topiramate, verapamil

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

osteoporosis

Top approved-drug candidatestinidazole, crizotinib, clotrimazole, glimepiride

CT.gov whitespace: untried

$3,950Details Acquire

Metabolic 12

S2 (505(b)(2))

Diabetes

Top approved-drug candidatesbithionol, ixazomib, menadione, clozapine

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Diabetic Gastroenteropathy

Top approved-drug candidatesniclosamide, mitoxantrone, mercaptopurine, dexrazoxane

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Gestational Diabetes Mellitus

Top approved-drug candidatesvalproic-acid, fluphenazine, trifluoperazine, tretinoin

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Metabolic Diseases

Top approved-drug candidatesestradiol, indometacin, terbutaline, troglitazone

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

Metabolic Syndrome

Top approved-drug candidatesmafenide, ziprasidone, bisacodyl, flunisolide

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

NASH

Top approved-drug candidatesvorinostat, orciprenaline, doxapram, cyproheptadine

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Obesity

Top approved-drug candidatesnaproxen, imiquimod, nifedipine, lapatinib

Prior clinical activity

$3,950Details Acquire

Repurposing report

Top approved-drug candidatesranked candidates

Whitespace: under review

$3,950Details Acquire

S2 (505(b)(2))

Type 1 Diabetes

Top approved-drug candidatestivozanib, epirubicin, selumetinib, idarubicin

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Type 2 Diabetes

Top approved-drug candidatesbrimonidine, perhexiline, cilostazol, trazodone

Prior clinical activity

$3,950Details Acquire

S2 (505(b)(2))

fatty liver disease

Top approved-drug candidatesvalproic-acid, chlorpromazine, glibenclamide, troglitazone

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

type 2 diabetes mellitus

Top approved-drug candidatesdimercaptosuccinic-acid, retinol, mepyramine, vorinostat

Prior clinical activity

$3,950Details Acquire

Aging & Longevity 6

S3 (505(b)(2)+Orphan) · Orphan-eligible

Hutchinson-Gilford Progeria Syndrome

Top approved-drug candidatesprima-1-met, navitoclax, valproic-acid, RHO-kinase-inhibitor-III[rockout]

CT.gov whitespace: untried

$3,950Details Acquire

S3 (505(b)(2)+Orphan) · Orphan-eligible

Nestor-Guillermo Progeria Syndrome

Top approved-drug candidateslovastatin, perphenazine, hydroflumethiazide, fluspirilene

CT.gov whitespace: untried

$3,950Details Acquire

S2 (505(b)(2))

Premature Aging

Top approved-drug candidatessirolimus, vemurafenib, idarubicin, atorvastatin

CT.gov whitespace: untried

$3,950Details Acquire

Repurposing report

Top approved-drug candidatesranked candidates

Whitespace: under review

$2,450Details Acquire

S2 (505(b)(2))

Senescence

Top approved-drug candidatesartesunate, pindolol, fulvestrant, bosentan

Prior clinical activity

$3,950Details Acquire

S3 (505(b)(2)+Orphan) · Orphan-eligible

progeria

Top approved-drug candidatesruxolitinib, pravastatin, atorvastatin, fluspirilene

Prior clinical activity

$3,950Details Acquire